logo
Ozempic users say weightloss drugs are now chic — not shameful: ‘It makes me feel more established because I'm doing the same thing as celebrities'

Ozempic users say weightloss drugs are now chic — not shameful: ‘It makes me feel more established because I'm doing the same thing as celebrities'

New York Post11-06-2025

When Caley Svensson, a 41-year-old content creator, first started taking the weight-loss drug Mounjaro in July 2022, she kept mum about it.
If friends asked her explicitly if she was using a GLP-1 medication to shed pounds, she would be honest — but she often felt judged. Some pals made comments about how they could never give themselves a shot or asked if it was just another dangerous diet fad.
'It was like speed, no one thought this was a good solution,' said Svensson, who lives in Park Ridge, New Jersey.
9 Caley Svensson has lost nearly 100 pound on weight-loss medication.
Tamara Beckwith
9 She initially kept quiet about going on Mounjaro and faced judgement from friends. Now, she said, it seems like everyone's on the drugs.
Tamara Beckwith
Now, Svensson said, it seems like nearly everyone has gotten off their high horse — often to get on the medications themselves.
Like being in therapy, taking antidepressants or getting Botox, using weight-loss medications such as Ozempic and Mounjaro has gone from being a secretive and sometimes shameful practice to being considered chic. In certain circles everyone seems to be on them — so much so that it's almost a badge of honor.
'All the friends who judged me for it, half of them are on it now,' said Svensson, who has lost over 90 pounds. 'The dirty little secrets people used to have to stay thin, rich, and healthy, they are now out in the open.'
9 Here, Svensson is pictured before she went on the medication.
Courtesy of Caley Svensson
Morgan Stanley Research estimates that 24 million people in the US — roughly 7% of the population — will be taking these drugs by 2035.
Tyler McLoughlin, 32, who lives in Brooklyn and works as an associate director for student life at CUNY, likes the famous and fabulous connotations around the medications.
'All the Real Housewives are taking it, all the celebrities are taking it,' said McLoughlin, who has been on a semaglutide — the class of GLP-1s that include Ozempic and Wegovy — since October. 'It kind of makes me feel more established because I'm doing the same thing as celebrities are doing.'
He is also ecstatic about his new body. His 5-foot-7 frame has gone from 185 to 150 pounds.
9 Archana Pinnapureddy loves telling people about her success with tirzepatide.
Tamara Beckwith
'I was just in Miami this past weekend, and this is the first time in my whole life I felt comfortable wearing a Speedo,' he said. 'I just feel so excited and so proud.'
Archana Pinnapureddy, a 43-year-old tech entrepreneur, isn't just open about the fact that she's been taking tirzepatide, a drug whose brand names include Mounjaro and Zepbound, for the past year, she openly promotes the fact.
She posts about it on her social media channels and tells everyone she meets how great the medication has been for her.
'I am very happy with it. It has given me this new power, that I can be my best self. I can even fit into my college clothes again,' she said. 'You also save money on food and alcohol because you aren't eating and drinking as much when you go out.'
9 Archana (right) and her twin sister Kanchana have both had success slimming down with the drug.
Courtesy of Archana and Kanchana Pinnapureddy
9 Here, the two are pictured before going on the medication.
Courtesy of Archana and Kanchana Pinnapureddy
Pinnapureddy, who is 5-foot-1, has gone from 142 pound to 106 pounds. Her twin sister has had similar results.
'[We] joke that we are walking ads for this medication,' she enthused. 'I've encouraged so many people to get on it. Some people I referred it to dropped 15 pounds in a month.'
Nicholas Salza, 31 and a 911 dispatcher in Fairfield, CT, has been on tirzepatide since August 2024 and lost 125 pounds. He doesn't understand why anyone would hide or feel shame about something that can be such a boost to health.
'Why wouldn't you do something to help yourself, especially after failing in so many diets and workouts or committing to the gym for a couple of weeks and not sticking to it?' he said. 'When something works, why wouldn't you spread awareness to people who may be going through the same thing?'
9 Nicholas Salza weighed 425 pounds before (left) going on Tirzepatide. He now (right) weighs about 300 pounds.
9 'Why wouldn't you do something to help yourself, especially after failing in so many diets and workouts or committing to the gym for a couple of weeks and not sticking to it?' said Salza (pictured before his weight-loss).
Courtesy of Nicholas Salza
9 'When something works, why wouldn't you spread awareness to people who may be going through the same thing?' said Salza (pictured after he slimmed down).
Courtesy of Nicholas Salza
Pinnapureddy notes that even if she wanted to keep mum about being on a GLP-1, it would be a challenge.
'I feel like it's kind of obvious that you're on them if you were never skinny and all of a sudden boom, you're thin,' she said. 'It's rare that you can do that especially if you're in your late '30s and '40s.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing"
Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing"

Yahoo

timean hour ago

  • Yahoo

Novo Nordisk ends Wegovy sales on Hims & Hers over "deceptive marketing"

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San Francisco-based online health company sold "illegitimate, knockoff versions of Wegovy that put patient safety at risk." Novo Nordisk's move to dissolve the partnership came less than two months after the companies said they were entering a "long-term collaboration" to make obesity treatment more accessible. Shares of Hims & Hers plunged more than $20, or roughly 31%, to $44.10 following Novo Nordisk's announcement. Hims & Hers did not immediately respond to a request for comment. Novo Nordisk said it began selling Wegovy via telehealth companies, including Hims & Hers, after a nationwide shortage of the drug. In offering the drug through more retailers, Novo Nordisk said it wanted to shift patients from using "knock-off, compounded versions" of Wegovy to the Food and Drug Administration-approved semaglutide drug. "After over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," a Novo Nordisk spokesperson told CBS MoneyWatch. "This is unacceptable, and that is why we have decided to end the collaboration." The FDA approved Wegovy for adults with obesity in March 2024, adding it to an expanding market of weight-loss drugs that include Ozempic and Mounjaro. Demand for GLP-1 drugs, which are used to treat diabetes and weight loss, has surged in recent years, with one in eight U.S. adults saying they've used the treatments, according to health research publisher KFF. In its release, Novo Nordisk said a company investigation showed that the ingredients in knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China and that a large share of the drugs were never inspected by the FDA. "U.S. patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients," Novo Nordisk said. Novo Nordisk will continue to sell Wegovy on other telehealth platforms that "share our commitment to patient safety," said Dave Moore, executive vice president at Novo Nordisk, in the company's statement. Among the telehealth companies Novo Nordisk partners with are LifeMD and Ro. Kidney dialysis industry accused of maximizing profits over patients Pentagon officials reveal new details about U.S. strikes on Iran's nuclear sites Netanyahu reacts to U.S. strikes on Iranian nuclear sites

Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints

Yahoo

timean hour ago

  • Yahoo

Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints

U.S.-listed shares of Novo Nordisk fell more than 5% Monday after the Ozempic and Wegovy maker released results for its newest weight-loss treatment. In a pair of trials, patients lost an average of 22.7% and 15.7% of their body weight over a 68-week period. Separately Monday, Novo Nordisk also said it was ending its partnership with Hims & Hers Health, accusing the digital pharmacy of "illegal mass compounding and deceptive marketing."Novo Nordisk's (NVO) U.S.-listed shares fell more than 5% Monday after the drugmaker revealed the results of a Phase 3 trial for a new weight-loss treatment. The maker of Ozempic and Wegovy said that after a 68-week trial, obese and overweight patients who took CagriSema and followed a treatment plan lost an average of 22.7% of their body weight compared to 2.3% for those in the placebo group. About 40% of the group lost at least 25% of their body weight during the trial, and nearly a quarter lost 30% or more. Just 6% of the trial group stopped taking the drug, mainly due to gastrointestinal issues like nausea and constipation. Novo Nordisk also published results from a second trial Monday, evaluating the drug's effectiveness among overweight or obese patients with type 2 diabetes. At 68 weeks, the average weight loss was about 15.7% of a patient's body weight, and the company said the second trial had similar safety results as the first. Previous trial results for the drug weighed on Novo Nordisk's shares, as CagriSema has yet to achieve the average weight loss of 25% that the company has reportedly hoped for. Shares have also been pressured by trials showing that rival Eli Lilly's (LLY) Mounjaro and Zepbound, along with its drugs in development, are more effective at causing weight loss than Ozempic and Wegovy. U.S.-listed shares of Novo Nordisk are down 20% since the start of 2025 and have lost half their value over the past 12 months. Separately, Novo Nordisk said it has ended its partnership with digital pharmacy Hims & Hers Health (HIMS), and will no longer allow the company to prescribe Wegovy. The companies announced the collaboration in April, but on Monday Novo Nordisk accused Hims of "illegal mass compounding and deceptive marketing." Hims & Hers shares plummeted nearly 30% in recent trading. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices
Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices

CBS News

timean hour ago

  • CBS News

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices

Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm's weight-loss drug, Wegovy. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San Francisco-based online health company sold "illegitimate, knockoff versions of Wegovy that put patient safety at risk." Novo Nordisk's move to dissolve the partnership came less than two months after the companies said they were entering a "long-term collaboration" to make obesity treatment more accessible. Shares of Hims & Hers plunged more than $20, or roughly 31%, to $44.10 following Novo Nordisk's announcement. Hims & Hers did not immediately respond to a request for comment. Novo Nordisk said it began selling Wegovy via telehealth companies, including Hims & Hers, after a nationwide shortage of the drug. In offering the drug through more retailers, Novo Nordisk said it wanted to shift patients from using "knock-off, compounded versions" of Wegovy to the Food and Drug Administration-approved semaglutide drug. "After over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," a Novo Nordisk spokesperson told CBS MoneyWatch. "This is unacceptable, and that is why we have decided to end the collaboration." The FDA approved Wegovy for adults with obesity in March 2024, adding it to an expanding market of weight-loss drugs that include Ozempic and Mounjaro. Demand for GLP-1 drugs, which are used to treat diabetes and weight loss, has surged in recent years, with one in eight U.S. adults saying they've used the treatments, according to health research publisher KFF. In its release, Novo Nordisk said a company investigation showed that the ingredients in knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China and that a large share of the drugs were never inspected by the FDA. "U.S. patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients," Novo Nordisk said. Novo Nordisk will continue to sell Wegovy on other telehealth platforms that "share our commitment to patient safety," said Dave Moore, executive vice president at Novo Nordisk, in the company's statement. Among the telehealth companies Novo Nordisk partners with are LifeMD and Ro.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store